Melanoma’s personalized mRNA vaccine looks like a breakthrough—but the hardest questions remain

Melanoma’s personalized mRNA vaccine looks like a breakthrough—but the hardest questions remain
A personalized mRNA vaccine has produced one of the most encouraging results yet in melanoma treatment—but the trial’s early success is colliding with unanswered questions about durability, access and who will benefit.

The Australian-led phase III study followed 1,137 patients whose high-risk melanoma had been surgically removed. All received pembrolizumab, marketed as Keytruda, while some also received intismeran, a vaccine tailored to mutations in each patient’s tumor. After two years, 82% of patients given the combination were alive and recurrence-free, compared with 70% receiving pembrolizumab alone. The combination cut the risk of recurrence or death by 42%. That is why the treatment has been described as “a foundational shift in our approach to cancer.”

The optimistic interpretation is straightforward: unlike conventional targeted therapies aimed at one mutation, the bespoke vaccine can target up to 34 mutations unique to an individual melanoma. Researchers say it trains the immune system to recognize and destroy cancer cells before they return. The conservative framing is narrower but consistent with the data: the vaccine “helps reduce the chances of melanoma patients’ tumors returning,” rather than proving a cure.

That distinction matters. The trial has not yet shown whether the combination extends long-term survival, and the results still face peer review and regulatory scrutiny. Researchers also caution that a significant share of patients do not respond initially, while melanoma cells can adapt and evade treatment. The findings may therefore represent a major advance in preventing recurrence without yet establishing a universally effective therapy.

The next test is whether the approach works in patients with visible, active cancer or in those who do not respond to pembrolizumab. Until further studies and approvals are completed—potentially taking several years—the vaccine remains a powerful clinical signal, not a standard treatment.